期刊
ONKOLOGIE
卷 30, 期 5, 页码 253-255出版社
KARGER
DOI: 10.1159/000100930
关键词
gemcitabine; chemotherapy; atrial fibrillation
类别
Background: Gemcitabine, a pyrimidine analogue, is a cell cycle-specific antineoplastic agent that is structurally related to cytarabine. Major side effects of the treatment with gemcitabine are hepatic dysfunction, myelo-suppression, renal impairment and pulmonary toxicity. Development of atrial fibrillation (AF) during gemcitabine treatment is very rare and was reported in only 2 case reports in the literature. Case Report: We report the case of a 65-year-old man who developed AF under gemcitabine therapy for non-small cell lung cancer (stage IIIB). In this patient, AF was intrinsically associated with chemotherapy administration which triggered arrhythmia. Conclusion: Although AF caused by gemcitabine appears to be rare, patients at risk of developing atrial fibrillation should be closely monitored for this complication.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据